GICS sector is Information Technology; ROE>0.15; Gross Margin>0.35; p/e<20

What are the stocks with a P/E ratio lower than the industry average and a dividend yield exceeding 5%?

How to find hidden champions with continuously increasing market share in the consumer sector?

How should I invest in Recursion Pharmaceuticals now?

<h3 style="text-align: start">Is it bursting? Here&#39;s how to tell, and what to do about it</h3>Tech stocks have swooned in recent weeks. A reprieve seemed nigh on November 19, when chip giant Nvidia <a href="https://www.nytimes.com/2025/11/19/technology/nvidia-earnings.html" target='__blank'>reported blowout earnings</a>, demonstrating once again that there’s real revenue and profit in the artificial intelligence revolution.But Nvidia isn’t the whole story, and a low-speed tech selloff <a href="https://www.cnbc.com/2025/11/20/nvidia-shares-rise-after-after-stronger-than-expected-3q-results.html" target='__blank'>still seems to be underway</a>. Some seasoned investors are sounding the alarm on AI because they see warning signs that remind them of other bursting bubbles. One is irrational exuberance over a disruptive technology that might be getting ahead of itself. Another is the role of private lending to finance much of the spending, which is more opaque and possibly riskier than traditional financing.The upshot could be a market downturn similar to the dot-com bust that began in 2000 and lasted three years. Investors overexposed to AI or to tech in general could endure sharp losses they never saw coming.Here’s the lay of the land:

¶ Hundreds of firms across the economy are spending more than $100 billion per year on artificial intelligence systems, including power-hungry data centers, computing hardware and cloud infrastructure. This spending surge has almost single-handedly driven the stock-market boom of the last three years.<img data-json="{&quot;type&quot;:&quot;image&quot;,&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Rick AI bubble_3bfbec0b1765552840710.jpeg&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}]}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Rick AI bubble_3bfbec0b1765552840710.jpeg" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" />¶ Much of the borrowing that finances this buildout comes from private sources other than banks, such as private-equity firms, hedge funds and specialty finance companies. Some <a href="https://www.bloomberg.com/news/articles/2025-11-10/blackrock-eyes-100-loss-on-private-loan-amid-debate-over-marks" target='__blank'>familiar Wall Street firms</a> now have private credit arms, as well. This private credit is less regulated and less transparent than more traditional financing through banks. Some analysts see parallels to the reckless lending that inflated the subprime mortgage market in the early 2000s, and left many investors with PTSD that’s flaring now.¶ It would be normal for many of the AI bets these companies are placing to fail. Breakthrough technologies often generate speculative manias in which a small number of players become stratospheric successes while many go bust.¶ There’s sharp disagreement over whether AI will transform life as we know it or just amount to a glorified Google search. The market narrative, so far, has tilted toward transformation. But some prominent voices are now calling AI vastly overhyped.¶ Stocks and tech stocks in particular are at extremely high valuations. A correction would be normal, but a selloff could deepen if it exposes a lot of undercapitalized firms that can’t survive routine market stress. Some bigwigs think we’re already starting to see that.More from Rick Newman <a href="https://www.thepinpointpress.com/ " target='__blank'>The Pinpoint Press</a> <ul><li><a href="https://www.thepinpointpress.com/p/the-trump-economy-is-subpar" target='__blank'>The Trump economy is supbar</a></li></ul><ul><li><a href="https://www.thepinpointpress.com/p/the-trump-economy-is-subpar" target='__blank'></a><a href="https://www.thepinpointpress.com/p/why-low-gas-prices-arent-cheering" target='__blank'>Why low gas prices aren&#39;t cheering anybody up</a></li></ul><ul><li><a href="https://www.thepinpointpress.com/p/why-low-gas-prices-arent-cheering" target='__blank'></a><a href="https://www.thepinpointpress.com/p/the-other-affordability-problem-incomes" target='__blank'>The other affordability problem: Incomes are flatlining</a></li></ul><h2 style="text-align: start">Here are the possible elements of a bursting AI bubble:</h2>1. A souring AI narrative. The AI hype suggests bots and machines will soon be able to reason like humans and do much of the work people can do. But there are skeptics. Banking analyst Chris Whalen calls AI a “global marketing con.” He <a href="https://www.theinstitutionalriskanalyst.com/post/theira780" target='__blank'>wrote recently that</a> “most public companies are so invested in the false gospel of AI that they dare not even hint at the truth, namely that the vast majority of AI projects will never be profitable or even relevant.” AI giants such as <a href="https://rollcall.com/factbase/trump/transcript/donald-trump-remarks-thanksgiving-turkey-pardon-november-25-2025/" target='__blank'>OpenAI</a> and <a href="https://www.cnbc.com/2025/11/18/anthropic-ai-azure-microsoft-nvidia.html" target='__blank'>Anthropic</a>, for instance, are spending billions even though profits are years in the future.Yann LeCun, an AI progenitor who has been chief AI scientist at Meta, has been drawing converts to his <a href="https://www.wsj.com/tech/ai/yann-lecun-ai-meta-0058b13c?st=9iof7m&amp;mod=wsjreddit" target='__blank'>unconventional view</a> that the standard approach to training AI is a <a href="https://www.youtube.com/watch?v=qvNCVYkHKfg" target='__blank'>dead-end that will never yield anything near human-level intelligence</a>. LeCun recently said he’s leaving Meta to start a firm developing a different type of AI.2. Stretched valuations. Current stock values are extremely high, relative to earnings. Economist David Rosenberg of Rosenberg Research points out that by one measure, S&amp;P 500 valuations are higher than during any bubble of the last century except for the peak of the dot-com boom in 1999. “We are in the stratosphere,” he says.By Rosenberg’s estimation, stock prices hit bubble levels in June 2024. The typical bubble lasts 16 months before it bursts. Last month would have marked the 16-month point. For what it’s worth, the tech-laden NASDAQ index hit its last record high on October 29. It’s down nearly 8% since then. 🤔3. Dodgy financing. There’s been about <a href="https://www.federalreserve.gov/econres/notes/feds-notes/the-state-of-ai-competition-in-advanced-economies-accessible-20251006.htm#fig1" target='__blank'>$500 billion in AI investment in the United States</a> during the last 10 years. The pace of investment now is about $110 billion per year. Much of that is borrowed money, and much of that comes from private sources that face little regulation and don’t have to disclose their obligations the way banks do. Private lending is still a small portion of all lending, but it probably accounts for a much bigger chunk of riskier gambits on AI.There’s nothing inherently wrong with private credit. But insiders say this is where the froth is forming, with private lenders seeking outsized returns by gambling on AI ventures that may never be profitable. Billionaire Jeff Gundlach, CEO of DoubleLine Capital, <a href="https://finance.yahoo.com/news/bond-king-jeffrey-gundlach-warns-201825636.html" target='__blank'>said recently that</a> “in recent years, garbage lending has gone to these private markets.” Public markets, by contrast, have much better lending standards than they did during the subprime mortgage explosion, which led to the financial crash of 2008.4. Cockroaches. Most people haven’t noticed, but a few firms have gone bust recently in surprisingly dramatic fashion, including <a href="https://www.kbb.com/car-news/a-big-auto-lender-went-bankrupt-heres-what-it-means/" target='__blank'>subprime auto lender Tricolor Holdings</a>, <a href="https://www.theguardian.com/business/2025/oct/18/what-is-private-credit-us-first-brands-tricolor-banks" target='__blank'>auto-parts company Frist Brands</a> and <a href="https://www.bloomberg.com/news/articles/2025-11-10/blackrock-eyes-100-loss-on-private-loan-amid-debate-over-marks" target='__blank'>Renovo Home Partners</a>. Those firms relied on private credit for their financing, and they essentially collapsed with almost no warning. That suggests terrible oversight by their lenders, and possibly fraud.“My antenna goes up when things like that happen,” JPMorgan Chase CEO Jamie Dimon <a href="https://www.cnn.com/2025/10/16/business/jamie-dimon-us-economy-cockroaches" target='__blank'>said in October</a>. “When you see one cockroach, there are probably more.” These failures were not AI companies, but many analysts point out that small failures in the early days of the subprime collapse in 2006 heralded much worse things to come.5. Dot-com scale. What’s happening in AI right now is not on the scale of the subprime wipeout that led to the 2008 financial crash. That crisis metastasized throughout the banking system and <a href="https://bettermarkets.org/wp-content/uploads/2021/07/Better-Markets-Cost-of-the-Crisis_1.pdf" target='__blank'>cost Americans as much as $20 trillion in lost wealth</a>, along with 9 million jobs. We’re not heading for another full-blown financial crisis.An AI bust could resemble the dot-com bust, however, which is hardly reassuring. That extended selloff <a href="https://corporatefinanceinstitute.com/resources/career-map/sell-side/capital-markets/dotcom-bubble/" target='__blank'>caused around $5 trillion in investor losses</a>, which would be about $9 trillion today—roughly two Nvidias. Of course, the dot-com boom that preceded the bust did bring us Amazon, Google, Nvidia itself and many other titans of today’s digital economy. So you could argue that investor losses from 2000 to 2002 turned into gains for those who held on. Huge gains, for those who held long enough.6. The AI defenders. Some important players think there’s no AI bubble to burst. Red-hot Nvidia is the biggest beneficiary of AI spending, and unlike many of those dot-com darlings of 25 years ago, it has gargantuan profits. Net income for the current year is likely to hit $114 billion, according to Capital IQ, with an eye-popping profit margin of 54%. “There’s been a lot of talk about an AI bubble,” CEO Jensen Huang <a href="https://www.cnbc.com/2025/11/19/nvidias-huang-rejects-ai-bubble-we-see-something-very-different.html" target='__blank'>said after the company reported quarterly earnings on November 19</a>. “From our vantage point we see something very different.”7. What should ordinary investors do? Certainly not panic. Gundlach says investors should lower their stock allocation to 40% of their portfolio, and most of that should be outside the United States. But that’s not realistic for many ordinary investors, who have to book capital gains and pay taxes if they sell assets to move money around. For anybody worried about a bubble, it’s more realistic to allocate new investments to safer assets. Investors should also be sure they know the risk of any newfangled products—such as private-credit vehicles—they may have heard about in financial media or from a broker.Perspective matters, too. David Kotok, cofounder of Cumberland Advisors, suggests we’re in the “middle phase” of a cycle very similar to other transformative technologies. “The sequence in all of history is the same,” he says. “In the early phase, there’s rapid acceleration. The middle phase includes leverage. Too much leverage and that’s where we will see the pain.”Eventually, he says, “we will have applications that will be extraordinary, and worthy of investment.” Right now, we just aren’t sure which ones, or how long it will take. <a href=" https://www.thepinpointpress.com/ " target='__blank'>Subscribe to The Pinpoint Press</a> Contributor Biography:<img data-json="{&quot;type&quot;:&quot;image&quot;,&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Contributor_61c9c51a1765553428920.jpg&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}]}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Contributor_61c9c51a1765553428920.jpg" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" /><img data-json="{&quot;type&quot;:&quot;image&quot;,&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Contributor Disclaimer_9cc32ad41765553606265.jpg&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}]}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Contributor Disclaimer_9cc32ad41765553606265.jpg" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" />

Clustering Methods

us_middle_importance

Stock

tech

Machine Learning Algorithms

NorthAmerica

Unsupervised Learning

Tech

Semiconductor

US Tech

Artificial Intelligence

Nvidia

A step-by-step guide to the AI bubble

<img data-json="{&quot;id&quot;:&quot;8579b35b-7670-48bd-b8e9-ee0c21cdb157&quot;,&quot;type&quot;:&quot;image&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}],&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/ab36176d-6166-42d9-97ed-2cb9d1609207_1002466076524807303-IMG_80731_4ac3e4041765248139451.jpg&quot;}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/ab36176d-6166-42d9-97ed-2cb9d1609207_1002466076524807303-IMG_80731_4ac3e4041765248139451.jpg" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" /><ul><li>The SynCardia Total Artificial Heart (TAH) is the world&#39;s first and only commercially approved device in the US that fully replaces a failing human heart according to <a href="https://www.azbio.org/20-years-after-landmark-fda-approval-syncardia-remains-worlds-only-commercially-approved-total-artificial-heart" target='__blank'>AZBio</a> , serving as a bridge to transplant for patients with end-stage biventricular heart failure.</li></ul><ul><li>Picard Medical, Inc. (PMI), the parent company of SynCardia Systems, LLC, went public in 2025 and is pioneering next-generation innovations like the fully implantable Emperor TAH, which could expand the market by eliminating external drivers.</li><li>With heart failure affecting millions globally, the artificial heart sector holds significant growth potential, driven by technological advancements and an aging population.</li><li>Investing in PMI offers exposure to the medtech industry, but requires monitoring regulatory approvals, clinical trials, and market adoption, alongside risks like development delays and competition.</li><li>Evergreen opportunities in this field include long-term bets on biotech innovations, with historical precedents showing high returns for early investors in life-saving devices.</li></ul>The field of artificial hearts represents a pinnacle of medical innovation, blending engineering prowess with life-saving potential. At the forefront stands the SynCardia Total Artificial Heart (TAH), developed by SynCardia Systems, LLC, a subsidiary of Picard Medical, Inc. This device has transformed treatment options for patients with severe heart failure, offering a mechanical bridge to transplantation when no other alternatives exist. In this evergreen exploration, we&#39;ll delve into the technology behind the SynCardia TAH, its evolution under Picard Medical, and the broader implications for investors eyeing the burgeoning cardiac device market.A Brief History of Artificial Hearts and SynCardia&#39;s Role<img data-json="{&quot;id&quot;:&quot;3009c87a-26be-4a48-9fe8-138b4f5878d6&quot;,&quot;type&quot;:&quot;image&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}],&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/3deb2f33-736a-4b80-96a3-5939948568b8_image_5d0a4d7a1765248471892.png&quot;}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/3deb2f33-736a-4b80-96a3-5939948568b8_image_5d0a4d7a1765248471892.png" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" />The quest for an artificial heart dates back to the mid-20th century, with early prototypes like the Jarvik-7 making headlines in the 1980s for their groundbreaking but limited success. SynCardia Systems, founded in 2001, built on this legacy by commercializing the temporary Total Artificial Heart (TAH-t), which received FDA approval in 2004 as a bridge-to-transplant device. Over the years, the company faced challenges, including a 2016 bankruptcy filing, after which it was acquired by Versa Capital Management. In a pivotal move, Picard Medical, Inc. became the holding company, fully owning SynCardia and steering it toward new innovations. Today, the SynCardia TAH remains the only commercially available total artificial heart approved by the FDA and Health Canada, according to the <a href="https://picardmedical.com/press_releases/syncardia-completes-first-in-vivo-implantations-of-next-generation-emperor-total-artificial-heart/" target='__blank'>official website</a> , with over 2,100 implants worldwide. Its design mimics the natural heart&#39;s function, pumping blood to sustain life in patients awaiting a donor organ.<rich-table border='1' data="{&quot;columns&quot;:[{&quot;id&quot;:&quot;7a94265f-b09c-4bad-9992-5097fff64946&quot;,&quot;width&quot;:155},{&quot;id&quot;:&quot;3d5cccf4-6bb1-4dfc-b839-a4c10a761f5a&quot;,&quot;width&quot;:106},{&quot;id&quot;:&quot;b9f40259-c092-45fb-9eae-e73800ebfa5f&quot;,&quot;width&quot;:526}],&quot;tableWidth&quot;:787,&quot;id&quot;:&quot;00299b46-2083-4f14-a14c-c3ad3cd7ada3&quot;}" ><tbody data="{&quot;id&quot;:&quot;fa4815f8-4712-450e-87c6-4ec79aaeb125&quot;}" ><tr data="{&quot;id&quot;:&quot;fc492e1c-aaef-450d-97ea-b138709b2882&quot;}"><td data="{&quot;id&quot;:&quot;566720cb-0e53-4ce7-963a-b705a7fd9255&quot;}">Milestone </td><td data="{&quot;id&quot;:&quot;94bca8fa-e1b8-4aee-b384-972cbf86e017&quot;}">Year </td><td data="{&quot;id&quot;:&quot;0162bc99-f469-4dd0-ad3e-05a72d7b2fed&quot;}">Description </td></tr><tr data="{&quot;id&quot;:&quot;254ad731-6b32-4aaf-80bf-6a9192bb7d11&quot;}"><td data="{&quot;id&quot;:&quot;e69e7266-1422-4429-a849-f0ac8cee9144&quot;}">Initial Development</td><td data="{&quot;id&quot;:&quot;48129aa0-8f09-41b4-b505-e21014ac4930&quot;}">1960s-1980s</td><td data="{&quot;id&quot;:&quot;cf95327a-5cf5-45d2-96da-1b548eb3d76a&quot;}">Early artificial heart concepts, including Jarvik-7, lay groundwork for modern devices. </td></tr><tr data="{&quot;id&quot;:&quot;8303e2d9-5011-438d-85f7-1b79184e0e41&quot;}"><td data="{&quot;id&quot;:&quot;e9f37a55-cf96-4c1e-8cfa-a94d39de9d08&quot;}">SynCardia Founding</td><td data="{&quot;id&quot;:&quot;6c7aecc7-3ff4-4690-a6dc-b53e076c5664&quot;}">2001 </td><td data="{&quot;id&quot;:&quot;3361e2e5-a24d-4e77-86b5-9598997e7c14&quot;}">Company established to commercialize TAH technology.</td></tr><tr data="{&quot;id&quot;:&quot;9c2624ca-41fb-4c3c-af85-2c78e06c1bf4&quot;}"><td data="{&quot;id&quot;:&quot;1f1a9cbb-1a7f-40cc-9df1-668e85bb9d65&quot;}">FDA Approval</td><td data="{&quot;id&quot;:&quot;7eda3446-f3fc-4df6-a2e9-c79c26ba468b&quot;}">2004</td><td data="{&quot;id&quot;:&quot;576032fd-202b-4a70-93f0-d05afed020a6&quot;}">SynCardia TAH approved as bridge-to-transplant</td></tr><tr data="{&quot;id&quot;:&quot;a91f02c3-15db-46fc-bc5a-009ced74e86e&quot;}"><td data="{&quot;id&quot;:&quot;ab25455b-d901-4403-8dff-e2bbf0dafe91&quot;}">Acquisition by Versa</td><td data="{&quot;id&quot;:&quot;8fc06900-bcb0-4957-878a-e9c551a50f29&quot;}">2016</td><td data="{&quot;id&quot;:&quot;2f9c3b52-9e34-42db-9870-a1baf13ad0b5&quot;}">Post-bankruptcy restructuring strengthens operations.</td></tr><tr data="{&quot;id&quot;:&quot;43026e60-a01e-4179-a973-64ae1ebac982&quot;}"><td data="{&quot;id&quot;:&quot;52bf75a9-7dd0-46c4-a8c0-542f9f5ec29c&quot;}">Picard Medical Ownership</td><td data="{&quot;id&quot;:&quot;d81e6cc2-b866-480c-8e38-7cf3d4573876&quot;}">2020s </td><td data="{&quot;id&quot;:&quot;60c9dac2-7ed2-4192-a442-06d796a47622&quot;}">Full integration and push toward next-gen Emperor TAH.</td></tr><tr data="{&quot;id&quot;:&quot;a1e2d333-84be-418c-8b9e-7ecdf18a4ff5&quot;}"><td data="{&quot;id&quot;:&quot;5d2cc693-099e-403a-aef6-40302ab9a449&quot;}">IPO and Public Trading</td><td data="{&quot;id&quot;:&quot;a59dc283-4c5f-4c2a-bb54-f6b09d8e8df2&quot;}">2025</td><td data="{&quot;id&quot;:&quot;eac562aa-684d-4979-bd33-f61de513a9e5&quot;}">Picard Medical goes public, raising funds for R&amp;D.</td></tr></tbody></rich-table>The Technology and Clinical ImpactAccording to <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3853833/" target='__blank'>National Institute of Health, </a>The SynCardia TAH is a pneumatic device that completely replaces both ventricles of the heart, connected to an external driver that powers its pulsatile flow. It is designed for patients with biventricular failure—where both sides of the heart are compromised—and has proven effective in stabilizing individuals until a transplant becomes available. Unlike ventricular assist devices (VADs) that support only one side, the TAH eliminates the failing heart entirely, reducing risks like blood clots from damaged tissue.Under Picard Medical&#39;s leadership, the focus has shifted to the Emperor TAH, a fully implantable version that promises greater patient mobility and quality of life by removing the need for external components. Recent in vivo implantations and presentations at conferences like ISMCS 2025 highlight its potential to expand the market. This advancement addresses limitations of the current model, positioning SynCardia as a leader in cardiac replacement therapy.Heart failure affects over 6 million Americans alone, with the global market for cardiac devices projected to grow significantly due to aging populations and rising chronic diseases. The SynCardia TAH&#39;s track record—over 20 years post-FDA approval—underscores its reliability, with ongoing R&amp;D enhancing its efficacy.Development Potential and Investment Opportunities<visualization data='{&quot;components&quot;:[{&quot;uuid&quot;:&quot;83b8ba4478495e35&quot;,&quot;config&quot;:{&quot;marketTag&quot;:&quot;AMEX&quot;,&quot;show_type_id&quot;:702,&quot;tradeClass&quot;:&quot;closed&quot;,&quot;title&quot;:&quot;KxxV2&quot;,&quot;fsType&quot;:&quot;closed&quot;,&quot;showBottom&quot;:true,&quot;showCodeContrast&quot;:false,&quot;score&quot;:20,&quot;show_type&quot;:&quot;kline3&quot;,&quot;maLine&quot;:[5,10,30,60],&quot;moduleList&quot;:[],&quot;variety&quot;:&quot;stock&quot;,&quot;scoreRuleNames&quot;:&quot;&quot;,&quot;tradeStatus&quot;:&quot;trading&quot;,&quot;codeName&quot;:&quot;Name&quot;,&quot;klineDefaultType&quot;:&quot;fs&quot;,&quot;title_config&quot;:{&quot;config&quot;:{&quot;display&quot;:true,&quot;display2&quot;:false,&quot;txt_style&quot;:0,&quot;url&quot;:&quot;&quot;},&quot;data&quot;:{&quot;h1&quot;:&quot;PMI Trend&quot;,&quot;h2&quot;:&quot;&quot;},&quot;show_type&quot;:&quot;title1&quot;}},&quot;data&quot;:{&quot;chunks_info&quot;:&quot;[]&quot;,&quot;code_count&quot;:1,&quot;columns&quot;:[{&quot;index_name&quot;:&quot;market_code&quot;,&quot;key&quot;:&quot;market_code&quot;,&quot;label&quot;:&quot;market_code&quot;,&quot;type&quot;:&quot;STR&quot;},{&quot;index_name&quot;:&quot;code&quot;,&quot;key&quot;:&quot;code&quot;,&quot;label&quot;:&quot;hq_code&quot;,&quot;source&quot;:&quot;fixed_index&quot;,&quot;type&quot;:&quot;STR&quot;},{&quot;domain&quot;:&quot;abs_xxxxxx&quot;,&quot;feKey&quot;:&quot;Ticker&quot;,&quot;index_name&quot;:&quot;Ticker&quot;,&quot;key&quot;:&quot;Ticker&quot;,&quot;label&quot;:&quot;code&quot;,&quot;origin_index&quot;:&quot;stock code&quot;,&quot;source&quot;:&quot;fixed_index&quot;,&quot;type&quot;:&quot;STR&quot;,&quot;unit&quot;:&quot;&quot;},{&quot;domain&quot;:&quot;abs_xxxxxx&quot;,&quot;feKey&quot;:&quot;Name&quot;,&quot;index_name&quot;:&quot;Name&quot;,&quot;key&quot;:&quot;Name&quot;,&quot;label&quot;:&quot;name&quot;,&quot;origin_index&quot;:&quot;stock name&quot;,&quot;source&quot;:&quot;fixed_index&quot;,&quot;type&quot;:&quot;STR&quot;,&quot;unit&quot;:&quot;&quot;},{&quot;feKey&quot;:&quot;Date&quot;,&quot;index_name&quot;:&quot;Date&quot;,&quot;key&quot;:&quot;Date&quot;,&quot;label&quot;:&quot;date&quot;,&quot;origin_index&quot;:&quot;Date&quot;,&quot;type&quot;:&quot;DATE&quot;},{&quot;domain&quot;:&quot;abs_xxxxxx&quot;,&quot;feKey&quot;:&quot;Closing Price&quot;,&quot;index_name&quot;:&quot;xxxx@Closing Price&quot;,&quot;key&quot;:&quot;Closing Price&quot;,&quot;label&quot;:&quot;NoIndent&quot;,&quot;report_type&quot;:&quot;TRADE_DAILY&quot;,&quot;source&quot;:&quot;&quot;,&quot;timestamp&quot;:&quot;&quot;,&quot;type&quot;:&quot;DOUBLE&quot;,&quot;unit&quot;:&quot;USD&quot;}],&quot;condition&quot;:&quot;[{\&quot;sonSize\&quot;:2,\&quot;opName\&quot;:\&quot;and\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:0,\&quot;indexName\&quot;:\&quot;xxxx@stock code\&quot;,\&quot;indexProperties\&quot;:[\&quot;EQUAL PMI.A\&quot;],\&quot;indexPropertiesMap\&quot;:{\&quot;EQUAL\&quot;:\&quot;PMI.A\&quot;},\&quot;domain\&quot;:\&quot;abs_xxxxxx\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:0,\&quot;indexName\&quot;:\&quot;xxxx@Closing Price\&quot;,\&quot;indexProperties\&quot;:[\&quot;xxxxxx 20251208\&quot;,\&quot;xxxxxx 20251208\&quot;],\&quot;indexPropertiesMap\&quot;:{\&quot;xxxxxx\&quot;:\&quot;20251208\&quot;,\&quot;xxxxxx\&quot;:\&quot;20251208\&quot;},\&quot;domain\&quot;:\&quot;abs_xxxxxx\&quot;,\&quot;relatedSize\&quot;:0}]&quot;,&quot;dataSize&quot;:1,&quot;datas&quot;:[{&quot;code&quot;:&quot;PMI&quot;,&quot;Ticker&quot;:&quot;PMI.A&quot;,&quot;market_code&quot;:&quot;170&quot;,&quot;Closing Price&quot;:&quot;2.87&quot;,&quot;Date&quot;:&quot;20251208&quot;,&quot;Name&quot;:&quot;Picard Medical&quot;}],&quot;meta&quot;:{&quot;extra&quot;:{}},&quot;row_count&quot;:1,&quot;status_code&quot;:0,&quot;status_msg&quot;:&quot;ok&quot;},&quot;category&quot;:&quot;generic&quot;,&quot;chart_type&quot;:&quot;&quot;,&quot;show_type&quot;:&quot;jgyKline3&quot;,&quot;title_config&quot;:{&quot;config&quot;:{&quot;display&quot;:true,&quot;display2&quot;:false,&quot;txt_style&quot;:0,&quot;url&quot;:&quot;&quot;},&quot;data&quot;:{&quot;h1&quot;:&quot;PMI Trend&quot;,&quot;h2&quot;:&quot;&quot;},&quot;show_type&quot;:&quot;title1&quot;},&quot;support_refresh&quot;:false,&quot;data_config&quot;:{&quot;data_ext_params&quot;:{},&quot;query_type&quot;:&quot;intusstock&quot;}}],&quot;global&quot;:{&quot;query_type&quot;:&quot;intusstock&quot;},&quot;page&quot;:{&quot;language&quot;:&quot;&quot;,&quot;layout&quot;:{&quot;layout_data&quot;:&quot;[{\&quot;showType\&quot;:\&quot;jgyKline3\&quot;,\&quot;uuid\&quot;:\&quot;83b8ba4478495e35\&quot;}]&quot;},&quot;render_for&quot;:&quot;aigc&quot;},&quot;query_condition&quot;:{},&quot;data_config&quot;:{&quot;data_ext_params&quot;:{},&quot;query_type&quot;:&quot;intusstock&quot;}}' dataurl='undefined'></visualization>Picard Medical&#39;s stewardship has injected fresh momentum into SynCardia, with investments funding the Emperor&#39;s development and clinical trials. As a publicly traded entity (PMI), the company offers investors direct exposure to this niche. The medtech sector, including artificial organs, is ripe for growth, with parallels to successful investments in devices like pacemakers or stents. Entry points for investors include monitoring milestones like FDA submissions for the Emperor, which could drive stock appreciation. With a market cap influenced by recent IPO proceeds of around $17-19 million, PMI represents a speculative but high-reward play in biotech. Broader trends, such as increasing demand for organ replacements amid donor shortages, bolster long-term potential.However, as with any medtech investment, patience is key—regulatory hurdles and clinical outcomes can sway valuations.FAQs for Aspiring Investors and Enthusiasts<img data-json="{&quot;id&quot;:&quot;e659ef70-eb75-49a6-b8ed-4da10926a50d&quot;,&quot;type&quot;:&quot;image&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}],&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/d0b95090-3679-4502-94eb-785a92454c90_image_e67fb0411765248500202.png&quot;}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/d0b95090-3679-4502-94eb-785a92454c90_image_e67fb0411765248500202.png" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" />1. How does the SynCardia Total Artificial Heart work, and why is it a game-changer for heart failure treatment?The SynCardia TAH is a mechanical pump that replaces the heart&#39;s ventricles, powered by an external driver to circulate blood throughout the body. It&#39;s revolutionary because it serves as a complete substitute for patients with both sides of the heart failing, providing a reliable bridge until a transplant is possible, unlike partial support devices that may not suffice in severe cases. For newcomers to medtech, this means it buys critical time, improving survival rates in a condition affecting millions.2. What key factors should I consider before investing in a company like Picard Medical?Before diving in, evaluate the company&#39;s pipeline (e.g., the Emperor TAH&#39;s progress), financial health via quarterly reports, and market trends like rising heart disease prevalence. Use resources like FDA and Medical Publications for basics on biotech valuation—start by setting up free accounts and tracking PMI&#39;s news feeds for informed decisions.3. What risks should I watch for when investing in artificial heart companies like PMI?Key risks include regulatory delays (e.g., FDA approvals), competition from rivals like Carmat, and high R&amp;D costs leading to dilution. Market volatility in biotech can cause sharp drops—always assess financial health via reports from SynCardia official website. Diversify to mitigate.4. How can I identify entry points for investing in medtech stocks during market fluctuations?Watch for catalysts like positive clinical trial results or regulatory milestones, which often lead to price surges—use alerts on AInvest Newswire to notify you of PMI updates. For beginners, consider dollar-cost averaging during dips, but always review analyst ratings on sites like Reuters to avoid buying at peaks.5. What portfolio strategies work well for including innovative biotech like PMI without overexposing myself?Aim for a balanced approach: allocate 5-10% of your portfolio to high-growth biotech like PMI, paired with stable ETFs in healthcare. Track long-term trends via <a href="https://ainvest.com/news/articles/latest/" target='__blank'>AInvest articles</a> on organ tech, and rebalance quarterly— this hedges against volatility while capturing upside from breakthroughs like fully implantable hearts.

us_low_importance

Medical Devices (Biotech)

Biotech

Implantable Devices

Therapeutic Innovations

Healthcare Equipment 

Picard Medical

Revolutionizing Heart Failure Treatment: The SynCardia Total Artificial Heart and Picard Medical's Investment Potential

<video src="https://www.youtube.com/embed/3jwE4MmOQwY" poster="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/CandPEpisode 19_45e37d951765548880746.jpg" data="{&quot;videoUrl&quot;:&quot;https://www.youtube.com/embed/3jwE4MmOQwY&quot;,&quot;coverUrl&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/CandPEpisode 19_45e37d951765548880746.jpg&quot;}"></video>Costco’s fiscal <a href="https://investor.costco.com/news/news-details/2025/Costco-Wholesale-Corporation-Reports-First-Quarter-Fiscal-Year-2026-Operating-Results/default.aspx" target='__blank'>first-quarter results</a> landed exactly where investors expect this company to live: quietly beating expectations, reinforcing its reputation as one of the most resilient retailers in the market, and simultaneously reminding everyone why the stock rarely looks cheap. The quarter did little to change the long-term narrative—Costco remains a best-in-class operator with extraordinary member loyalty—but it did sharpen the debate around growth normalization, tariffs, and how much upside is left at a premium valuation.On the headline numbers, Costco delivered a clean beat. Revenue came in at $67.31 billion, slightly ahead of the $67.14 billion consensus and up roughly 8.2% year over year. Earnings per share of $4.50 topped expectations of $4.27 and rose meaningfully from $4.04 a year ago, with adjusted earnings growth running in the low-to-mid teens once tax-related items are excluded. Comparable sales increased 6.4% globally, or about 7.1% when excluding gas prices and foreign exchange, a solid result given tough comparisons and a cooling inflation backdrop. Digitally enabled sales surged more than 20%, reinforcing that Costco’s omnichannel strategy continues to scale without undermining its warehouse-first model.The margin picture was consistent with Costco’s long-standing philosophy. Gross margin came in at 11.32%, up modestly year over year, while SG&amp;A edged slightly higher, driven in part by rising healthcare costs. There was no attempt by management to chase margin expansion aggressively, which is entirely on brand. Costco continues to prioritize price leadership and volume over squeezing incremental margin, and this quarter reinforced that discipline. Importantly, there was no sign of margin erosion tied to promotional activity, suggesting Costco is navigating a competitive retail environment without sacrificing profitability.From a consumer standpoint, the quarter painted a reassuring picture. Traffic increased about 3.1% globally, and average ticket size rose roughly 3.2%, indicating that growth is being driven by both higher visit frequency and slightly higher spend per trip—not simply price inflation. Management was clear that they are not seeing meaningful stress in the consumer, despite persistent narratives around inflation fatigue. Gas prices were modestly deflationary, which mechanically weighed on reported growth, but underlying demand trends remained healthy. Anecdotes from the call reinforced that message: record food court sales on Halloween, record U.S. e-commerce volume on Black Friday, and massive bakery volumes heading into Thanksgiving all point to a consumer that is still engaged and value-seeking rather than retrenching.That value-seeking behavior is exactly where Costco continues to shine. In an environment where consumers across income brackets are increasingly price conscious, Costco’s model—low margins, curated SKUs, and trusted pricing—remains uniquely advantaged. Management emphasized ongoing market share gains, particularly in non-food categories such as pharmacy, small appliances, apparel, tires, and jewelry, which all posted double-digit growth year over year. While growth rates have cooled compared to last year’s unusually strong non-food surge, the normalization appears more mathematical than fundamental.Tariffs were one of the more nuanced topics on the call. Management acknowledged that tariff uncertainty and logistical disruptions, including port-related issues, contributed to month-to-month “bumpiness” in sales trends. Costco’s scale and sourcing flexibility allow it to mitigate some of these pressures—through supplier negotiations, private-label Kirkland Signature, and shifts in sourcing—but not eliminate them entirely. The company emphasized that tariffs are being managed rather than ignored, and while they may create noise in reported results, they are unlikely to derail the broader operating model. Notably, investors are also watching the company’s ongoing IEEPA-related tariff litigation, which could represent upside optionality if refunds materialize, though management did not frame this as part of near-term guidance.Membership metrics remain the core pillar of the Costco story, and this quarter offered both reassurance and a watch point. Membership fee income rose 14% year over year to $1.329 billion, driven by continued member growth and the benefit of last year’s fee increase in the U.S. and Canada. Total paid members increased 5.2% to 81.4 million, while executive memberships grew 9.1% year over year to nearly 40 million. Renewal rates dipped modestly—down about 10 basis points sequentially to 92.2% in the U.S. and Canada and 89.7% globally—but management framed this as a function of higher digital sign-ups, which historically renew at lower rates initially. Importantly, they expressed confidence that renewal rates will stabilize and improve as digital engagement tools mature.Looking ahead, Costco’s outlook is deliberately steady rather than flashy. The company does not provide formal full-year guidance, but management reiterated plans to open roughly 28 net new warehouses in fiscal 2026, with a longer-term target of 30-plus openings per year. International expansion remains a key growth vector, particularly in underpenetrated markets such as France and Sweden, where early warehouse openings have seen strong member uptake. Capital expenditures are expected to run around $6.5 billion for the year, supporting new warehouses, remodels, and technology investments.Technology continues to play a growing, if understated, role. Digital membership scanning, app enhancements, and AI-driven inventory tools—particularly in pharmacy and fuel—are improving efficiency and member experience without changing the essence of the Costco model. E-commerce growth north of 20% shows that Costco can participate meaningfully in digital retail without sacrificing in-warehouse traffic, a balance many peers struggle to achieve.From a valuation perspective, this is where the conversation becomes more complicated. Even after some multiple compression over the past year, Costco still trades near the high end of the market, with a P/E approaching 50. That valuation reflects extraordinary business quality, consistency, and loyalty from both customers and shareholders—but it also limits near-term upside. The quarter did nothing to undermine the long-term bull case, but it also did not provide a catalyst for multiple expansion.For investors, the key things to watch going forward are straightforward. First, renewal rates—particularly among digitally acquired members—need to stabilize as management expects. Second, tariff-related volatility bears monitoring, especially if global trade frictions intensify. Third, the pace of international warehouse productivity will be critical as Costco leans more heavily on expansion outside North America. Finally, any signs of sustained pressure on traffic would be an early warning signal—but this quarter showed no such stress.Bottom line: Costco delivered another strong, reliable quarter that reinforced its status as a premier retail franchise. The business continues to perform exceptionally well, the consumer looks healthy, and execution remains disciplined. The stock, however, already reflects much of that excellence, suggesting future returns are more likely to be steady and incremental than explosive.

market

Splits

crypto

Forward Stock Splits

Financial Outlook

Revenue Guidance

Market Sentiment Impact

Guidance

Catalysts Analysis

Earnings

Top Gainers

Percentage Gains

Movers

Deals

New Retail

WallStreetBets

Logistic

Costco Wholesale

Costco Beat Earnings Again — and the Market Still Isn’t Impressed

U.S. equities opened Friday with modest, mixed moves as investors balanced a major federal policy shift on artificial intelligence, renewed scrutiny of richly valued technology stocks, and fresh evidence of mounting retirement shortfalls across the workforce.At the opening bell, the Dow Jones Industrial Average rose 72.49 points, or 0.15%, to 48,776.5. The Nasdaq Composite fell 85.99 points, or 0.36%, to 23,507.9, while the S&amp;P 500 slipped 9.75 points, or 0.14%, to 6,891.25. The Russell 2000 edged up 0.14 points, or 0.05%, to 257.94, signaling relative stability in small-cap shares.The hard truths about building wealth👇 <video src="https://www.youtube.com/embed/3jwE4MmOQwY" poster="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Episode 19_cd1720c41765549269258.jpg" data="{&quot;videoUrl&quot;:&quot;https://www.youtube.com/embed/3jwE4MmOQwY&quot;,&quot;coverUrl&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Episode 19_cd1720c41765549269258.jpg&quot;}"></video>Market volatility remained subdued, with the Cboe Volatility Index (VIX) ticking up 0.05 points to 14.90, reflecting limited near-term stress despite crosscurrents in policy and earnings.A key policy catalyst arrived overnight. President Donald Trump signed a sweeping executive order establishing a single federal regulatory framework for artificial intelligence, a move aimed at curbing a fragmented patchwork of state rules. According to Wedbush Securities, the order removes “significant regulatory hurdles” by bringing AI oversight under one federal standard while preserving incentives for innovation. The order also creates an AI Litigation Task Force, directs the Securities and Exchange Commission to review disclosure and transparency rules for advisers, and instructs the Federal Trade Commission to investigate deceptive practices in AI markets. Wedbush analysts said the move was designed to reinforce U.S. leadership in what they described as an “AI arms race” with China and to prevent state-level regulation from stifling startup formation and large-scale infrastructure investment.<visualization data='{&quot;components&quot;:[{&quot;show_type&quot;:&quot;jgyKline3&quot;,&quot;config&quot;:{&quot;codeName&quot;:&quot;name&quot;,&quot;marketTag&quot;:&quot;NASDAQ&quot;,&quot;variety&quot;:&quot;Stock&quot;,&quot;showBottom&quot;:true,&quot;moduleList&quot;:[],&quot;maLine&quot;:[5,10,20]},&quot;title_config&quot;:{&quot;config&quot;:{&quot;display&quot;:true},&quot;data&quot;:{&quot;h1&quot;:&quot;Broadcom Inc. (AVGO)&quot;}},&quot;data&quot;:{&quot;datas&quot;:[{&quot;code&quot;:&quot;AVGO&quot;,&quot;name&quot;:&quot;Broadcom Inc.&quot;,&quot;market_code&quot;:&quot;185&quot;}]},&quot;uuid&quot;:&quot;945c20c3168cc523&quot;},{&quot;show_type&quot;:&quot;jgyKline3&quot;,&quot;config&quot;:{&quot;codeName&quot;:&quot;name&quot;,&quot;marketTag&quot;:&quot;NASDAQ&quot;,&quot;variety&quot;:&quot;Stock&quot;,&quot;showBottom&quot;:true,&quot;moduleList&quot;:[],&quot;maLine&quot;:[5,10,20]},&quot;title_config&quot;:{&quot;config&quot;:{&quot;display&quot;:true},&quot;data&quot;:{&quot;h1&quot;:&quot;Broadcom Inc. (AVGO)&quot;}},&quot;data&quot;:{&quot;datas&quot;:[{&quot;code&quot;:&quot;AVGO&quot;,&quot;name&quot;:&quot;Broadcom Inc.&quot;,&quot;market_code&quot;:&quot;185&quot;}]},&quot;uuid&quot;:&quot;945c20c3168cc523&quot;}],&quot;page&quot;:{&quot;layout&quot;:{&quot;layout_data&quot;:&quot;[{\&quot;showType\&quot;:\&quot;jgyKline3\&quot;,\&quot;uuid\&quot;:\&quot;945c20c3168cc523\&quot;}]&quot;},&quot;render_for&quot;:&quot;aigc&quot;,&quot;tracking_info&quot;:{}}}' dataurl='undefined'></visualization>Technology investors, however, continued to show less tolerance for ambiguity around margins. Shares of major AI-linked companies have faced heightened scrutiny following recent earnings, most notably Broadcom’s fiscal fourth-quarter report. While the company <a href="https://www.ainvest.com/news/broadcom-beat-raised-sold-good-ai-earnings-aren-good-anymore-2512/" target='__blank'>exceeded revenue and earnings</a> expectations and guided higher for the current quarter, investors focused on management’s acknowledgment that the fastest-growing AI-related businesses carry lower margins. According to company commentary, AI semiconductor revenue is expected to double year over year to $8.2 billion in the first quarter, but margin compression tied to system sales and third-party components has raised concerns about valuation sustainability .Beyond technology, longer-term structural pressures also featured in investor discussions. New data highlighted the depth of the U.S. retirement savings gap. According to analysis by Torsten Slok, chief economist at Apollo Global Management, fewer than one in six workers aged 45 to 54 are contributing the maximum amount to their 401(k) plans. <img data-json="{&quot;type&quot;:&quot;image&quot;,&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/121225-Chart_v2_ce0b49af1765550195167.jpg&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}]}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/121225-Chart_v2_ce0b49af1765550195167.jpg" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" />The shortfall is particularly acute among younger cohorts, where participation rates are far lower, underscoring what Apollo describes as a growing retirement crisis amid rising living costs and the eventual depletion of the Social Security trust fund. The findings draw on data from Vanguard’s How America Saves 2025 report and point to the risk that inadequate household savings could weigh on long-term economic stability .Taken together, Friday’s opening tone reflects a market recalibrating expectations. Federal policy is moving to clear a path for large-scale AI investment, but equity valuations, especially in technology, are increasingly sensitive to execution and profitability. At the same time, demographic and savings trends highlight longer-term challenges that could influence consumption and capital markets in the years ahead.<video src="https://www.youtube.com/embed/U5GXAOrYWGE" poster="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/ARE YOU FINANCIALLY READY_179c67ec1765549692835.jpg" data="{&quot;videoUrl&quot;:&quot;https://www.youtube.com/embed/U5GXAOrYWGE&quot;,&quot;coverUrl&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/ARE YOU FINANCIALLY READY_179c67ec1765549692835.jpg&quot;}"></video>

Stock Investment Strategies

Call Options

personal_finance

Earnings Prospects

Long-Term Calls

MktOptions

Growth Investing

Investor Perception

Reverse Stock Splits

Investing

Volatility Considerations

U.S. Stocks Open Mixed as Investors Weigh AI Policy Shift, Earnings Scrutiny and Retirement Pressures

<video src="https://www.youtube.com/embed/3jwE4MmOQwY" poster="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/CandPEpisode 19_e482c69a1765547815759.jpg" data="{&quot;videoUrl&quot;:&quot;https://www.youtube.com/embed/3jwE4MmOQwY&quot;,&quot;coverUrl&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/CandPEpisode 19_e482c69a1765547815759.jpg&quot;}"></video>Broadcom’s fiscal <a href="https://investors.broadcom.com/news-releases/news-release-details/broadcom-inc-announces-fourth-quarter-and-fiscal-year-2025" target='__blank'>Q4 print</a> had all the ingredients of a “good” AI quarter: a clean beat on revenue and EPS, better-than-feared margins, and guidance that cleared the bar. And yet, the stock still slid hard after the call. The message from the tape is the same one investors got earlier in the week from Oracle: AI is no longer an “everyone wins” trade, and the market is now grading on a curve where “beat-and-raise” is just the entry fee. For AVGO, the culprit wasn’t demand. It was the mix, the margin trajectory, and a valuation that doesn’t tolerate any hint of gravity.Start with the numbers. Broadcom reported Q4 revenue of $18.015B versus roughly $17.46–$17.50B expected, and adjusted EPS of $1.95 versus $1.87 expected. The beat was supported by strong profitability: adjusted EBITDA was $12.218B (above expectations) with EBITDA margin around 68% (about 100 bps ahead of consensus). Free cash flow was also substantial at $7.5B, or about 41% of revenue, reinforcing that this is still an extremely cash-generative franchise even as it leans harder into AI and continues digesting VMware. In a vacuum, this is exactly the kind of quarter that usually gets rewarded.Guidance, on the surface, was also the opposite of a miss. For fiscal Q1, Broadcom guided revenue to about $19.1B versus Street expectations around $18.3–$18.4B. Management also guided adjusted EBITDA margin to roughly 67% of revenue. That’s a very strong profitability level in absolute terms, and it implies continued top-line momentum into the January quarter. The company sweetened the shareholder-return story with a 10% dividend increase to $0.65 per share for fiscal 2026. Again: not the profile of a company waving a caution flag. <a href="https://www.barrons.com/articles/broadcom-avgo-earnings-stock-price-27cb2bea?mod=hp_LEDE_C_3" target='__blank'>So why the selloff?</a> Because the call was a reminder that the fastest-growing part of Broadcom’s business is also lower margin, and it’s about to become a bigger slice of the pie. Management explicitly framed it: AI revenue carries lower gross margins than the rest of the business, and margins will “start to deteriorate” as the AI mix rises and as system sales ramp, particularly when Broadcom is effectively passing through more third-party components that dilute percentage margins. They tried to offset the concern with the more important concept—gross profit dollars and operating profit dollars should still grow, and operating leverage can still work even if margin percentage compresses. The market’s response was basically: understood, but at forty-plus times earnings, we’re not paying premium multiple for “margin down, dollars up” unless the upside is unmistakable.The AI commentary itself was undeniably strong. Management said AI semiconductor revenue is expected to double year-over-year in Q1 to $8.2B, driven by custom AI accelerators (ASICs/XPUs) and Ethernet AI switches. They also reiterated the scale of demand visibility: AI backlog in excess of $73B, expected to be delivered over the next 18 months—nearly half of the company’s total backlog. On customers, the call provided both reassurance and a new set of questions. Broadcom identified the previously referenced $10B “new qualified customer” as Anthropic and said it placed an additional $11B order for delivery in late 2026. Management also cited a fifth AI customer with a $1B order for late 2026. That expands the roster beyond the usual names (Meta, ByteDance, Google), which matters because “AI concentration risk” is one of the first things investors attack when a stock is priced like a royalty stream.But the market wanted either (1) more customer breadth, sooner, or (2) cleaner margin optics, now. Instead, it got a nuanced answer: there is a multi-year OpenAI partnership, but management doesn’t expect much revenue from OpenAI in 2026, with a ramp beginning in 2027 and extending through 2029. In other words, some of the “dream scenario” demand is real, but it’s back-half weighted. That’s fine for the business, but it complicates the stock when investors are already jumpy about the AI spending cycle, and when the nearest-term margin narrative is “down 100 bps sequentially in Q1 due to mix.”The backdrop matters here. After a year where AI winners could stumble and still levitate, the market is tightening the screws. The combination of an AI-heavy tape, high index valuations, and a growing belief that “the easy part is over” means there’s less patience for anything that looks like peak margins, peak excitement, or peak multiple. Oracle’s post-earnings drop earlier in the week contributed to that tone: even if the specific issues differ (Oracle’s centered on capex and cash burn versus Broadcom’s margin mix), the broader read-through is that investors are shifting from “AI demand exists” to “AI demand exists, but who captures the economics?”That brings us to valuation. Broadcom is being valued like a premier AI compounder, not a diversified semi + software platform with moving parts. Around “forty-plus times earnings” (as one market participant put it), the market is implicitly assuming sustained AI growth, continued success in networking (including the Tomahawk 6 switch ramp and strong AI switch backlog), and steady execution in Infrastructure Software (VMware Cloud Foundation adoption and bookings strength). It’s also why the “valuation gap” conversation shows up: if NVDA is the AI standard-bearer, AVGO is often treated like the highest-quality “second derivative” with a custom silicon angle. That’s flattering—until the market decides it would like the multiple to come with fewer caveats.What should investors watch from here?First, the margin path versus the growth path. Management is telling you percentage margins can compress while dollar profits still rise. The stock will trade on whether that’s credible quarter after quarter, especially as system sales increase and pass-through content grows. If gross margin percentage slides faster than expected, the multiple will compress even if revenue is strong.Second, conversion of backlog into reported revenue and the durability of the customer pipeline. The $73B backlog number is big enough to anchor the bull case, but investors will want evidence that it broadens beyond a handful of counterparties and that delivery timing doesn’t slip.Third, the OpenAI timeline. “Not much in 2026, ramps in 2027” is honest guidance, but it means the market will constantly debate whether the stock is pricing 2027 in 2025. Any incremental clarity on scope, volume, or timing can matter disproportionately.Fourth, non-AI stabilization. Management flagged non-AI semis as modestly growing and software as steady, but bears will keep probing whether “everything that isn’t AI” is stalling. Broadcom doesn’t need non-AI to be a rocket ship, but it can’t become dead weight.Fifth, supply chain and advanced packaging. Management highlighted investments (including Singapore advanced packaging capacity) to support AI demand. Investors will watch whether Broadcom can scale delivery without adding cost friction that worsens the very margin narrative the market is punishing.Bottom line: Broadcom delivered a beat and raised the near-term top line, but it also confirmed that the next phase of the AI buildout is less about whether demand exists and more about who captures the economics. If you want the stock to levitate from here, you probably need either re-acceleration in AI upside (more customers, more orders, more near-term visibility) or proof that margins won’t decay as quickly as the market fears. In the current tape, “phenomenal demand but slightly less phenomenal margins” is still good business—just not always good enough for a stock priced for perfection.

Volatility Metrics

Intraday Volatility

Prices

Technical Indicators

Chip Stocks

Broadcom

Broadcom Beat, Raised, and Still Sold Off: Why ‘Good’ AI Earnings Aren’t Good Enough Anymore

UK autos within rate quota subject to 7.5% tariff: US not

GPT-5.2 Debuts With Breakthrough Professional Performance

Wall Street Is Bracing for the Biggest IPO in History — And It Might Reshape the Entire Space Economy

Zelenskiy: Attack proves Russia does not take diplomatic efforts to end war seriously

Cautious Hover as Market Hits a Key Hurdle, AI Fatigue Builds — Prepare for More Volatility Ahead

Supertanker Skipper seized by the US near Venezuela heading to Houston, according to sources

Are You Financially Ready for Divorce? BMO Survey Finds Many Wealthy Women Are Not

Bessent says Treasury's FinCEN to issue investigation notices to money services businesses of concern

Oracle shares extend decline to 6.5%

Goldman Sachs sets S&P500 2026 target at 7600 - CNBC

Ukrainian drones hit primary crude distillation unit loading rack at Russia's Slavneft-Yanos oil refinery in Yaroslavl, according to industry sources

Russia's Slavneft-Yanos oil refinery suspended output - sources

Tilray up 40% as Trump expected to ease cannabis restrictions

Market Overview for Polkadot/Tether (DOTUSDT)

Market Overview for The Sandbox/Tether (SANDUSDT)

SPY Options Signal Deep Put Dominance: How Traders Can Hedge or Capitalize on the 680–690 Range

Pyth Network's Revenue-Backed Buybacks and Governance-Driven Value Capture: A Tokenomics-Driven Investment Thesis

The Economic Philosophy of Thomas Sowell and Its Implications for Policy-Driven Markets

Bitcoin at a Pivotal Inflection Point: Realized Losses Signal Accumulation, Not Capitulation

Meta (META) Options Signal $700 Call Contention as Short-Term Bearish Momentum Meets AI-Driven Optimism – Here’s How to Position

The Risk and Opportunity in Remittance-Based Economies Amid U.S. Regulatory Crackdowns

Amazon (AMZN) Options Signal $230–$240 Battle: Call Overhang and Whale Moves Point to Strategic Entry Zones

Tether's Tokenized Equity as a Game Changer in Private Market Liquidity

Analyzing Bluerock Acquisition Corp.'s $172.5M IPO: A Strategic SPAC Play in a Post-2025 Market?

Broadcom's Market Volatility and Strategic Implications for Tech Investors

Ainvest Option Flow Daily Digest - 2025-09-19 

Buying Oracle Shares Won't Make You As Rich As Larry Ellison, But Not Doing So Will Surely Leave You With Regret 

Micron’s AI Memory Machine Keeps Humming—But the Tape Wants Even More

UBS Sees Tesla Exceeding 500K Q3 Deliveries, New Record Ahead

Latest

Market Overview for Polkadot/Tether (DOTUSDT)

Market Overview for The Sandbox/Tether (SANDUSDT)

SPY Options Signal Deep Put Dominance: How Traders Can Hedge or Capitalize on the 680–690 Range

Pyth Network's Revenue-Backed Buybacks and Governance-Driven Value Capture: A Tokenomics-Driven Investment Thesis

The Economic Philosophy of Thomas Sowell and Its Implications for Policy-Driven Markets

Bitcoin at a Pivotal Inflection Point: Realized Losses Signal Accumulation, Not Capitulation

Meta (META) Options Signal $700 Call Contention as Short-Term Bearish Momentum Meets AI-Driven Optimism – Here’s How to Position

The Risk and Opportunity in Remittance-Based Economies Amid U.S. Regulatory Crackdowns

Amazon (AMZN) Options Signal $230–$240 Battle: Call Overhang and Whale Moves Point to Strategic Entry Zones

Tether's Tokenized Equity as a Game Changer in Private Market Liquidity

Analyzing Bluerock Acquisition Corp.'s $172.5M IPO: A Strategic SPAC Play in a Post-2025 Market?

Broadcom's Market Volatility and Strategic Implications for Tech Investors

US stocks

Trending tickers

Stocks gainers

Stocks losers

Crypto

Trending cryptos

Crypto gainers

Crypto losers